Feed ARGX
AR

Argenx ARGX · NASDAQ

$927.21 +3.63% (+$32.44)

Summary

69 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 31 USD is left as net profit.
  • Revenue grew by 116% a year over the last 3 years.
  • It holds more cash than debt: $3.58B against $47.0M.
  • Analysts expect revenue to grow by 53% this fiscal year.

What to watch

  • You pay 44.2 USD for 1 USD of yearly profit, a lot for its sector.
  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Current price $927.21
P/E today 44.2
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 44.2 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 152% a year over 5 years. Over the last 3 years it grew by 116% a year. For the next fiscal year analysts expect revenue to grow by 53%.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $1,134 is 22% above today's price. 89% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

The company reports no revenue by product.

By region

UNITED STATES brings in 85% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy